Login to Your Account

Novartis' Second Buyout Bid, $5.1B, Gains Chiron's Favor

By Randall Osborne

Tuesday, November 1, 2005
Though still haunted by questions about its management's handling of flu vaccine production, Chiron Corp. got a not-unexpected Halloween treat from Novartis AG, which upped to $5.1 billion its offer to buy out the company - and this time Chiron is recommending that shareholders approve. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription